Literature DB >> 8112408

The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1.

D Martin1, M A Thompson, J V Nadler.   

Abstract

Riluzole is believed to exert its anticonvulsant and neuroprotective actions by reducing glutamate release. This study demonstrated that 10-30 microM riluzole reduces the K(+)-evoked release of glutamate and aspartate from slices of hippocampal area CA1. Only higher concentrations reduced gamma-aminobutyrate (GABA) release. These actions of riluzole were not occluded by tetrodotoxin. Riluzole did not diminish the ability of glutamate analogues to depolarize CA1 pyramidal cells, as determined from grease-gap recordings. Therefore the anticonvulsant and neuroprotective actions of riluzole in the hippocampus may be at least partly explained by its ability to inhibit glutamate/aspartate release from synaptic terminals.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8112408     DOI: 10.1016/0014-2999(93)90037-i

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  52 in total

1.  Riluzole does not have an acute effect on motor thresholds and the intracortical excitability in amyotrophic lateral sclerosis.

Authors:  M Sommer; F Tergau; S Wischer; C D Reimers; W Beuche; W Paulus
Journal:  J Neurol       Date:  1999-11       Impact factor: 4.849

2.  Preclinical evaluation of riluzole: assessments of ethanol self-administration and ethanol withdrawal symptoms.

Authors:  Joyce Besheer; Veronique Lepoutre; Clyde W Hodge
Journal:  Alcohol Clin Exp Res       Date:  2009-08       Impact factor: 3.455

3.  Fluoxetine and Riluzole Mitigates Manganese-Induced Disruption of Glutamate Transporters and Excitotoxicity via Ephrin-A3/GLAST-GLT-1/Glu Signaling Pathway in Striatum of Mice.

Authors:  Zhipeng Qi; Xinxin Yang; Yanqi Sang; Yanan Liu; Jiashuo Li; Bin Xu; Wei Liu; Miao He; Zhaofa Xu; Yu Deng; Jinghai Zhu
Journal:  Neurotox Res       Date:  2020-05-29       Impact factor: 3.911

4.  Molecular mechanisms of interaction between the neuroprotective substance riluzole and GABA(A)-receptors.

Authors:  K Jahn; F Schlesinger; L J Jin; R Dengler; J Bufler; K Krampfl
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-05-06       Impact factor: 3.000

5.  The molecular tweezer CLR01 inhibits aberrant superoxide dismutase 1 (SOD1) self-assembly in vitro and in the G93A-SOD1 mouse model of ALS.

Authors:  Ravinder Malik; Helen Meng; Piriya Wongkongkathep; Christian I Corrales; Niki Sepanj; Ryan S Atlasi; Frank-Gerrit Klärner; Thomas Schrader; Melissa J Spencer; Joseph A Loo; Martina Wiedau; Gal Bitan
Journal:  J Biol Chem       Date:  2019-01-02       Impact factor: 5.157

6.  Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole.

Authors:  Brian P Brennan; James I Hudson; J Eric Jensen; Julie McCarthy; Jacqueline L Roberts; Andrew P Prescot; Bruce M Cohen; Harrison G Pope; Perry F Renshaw; Dost Ongür
Journal:  Neuropsychopharmacology       Date:  2009-12-02       Impact factor: 7.853

7.  The Effect of Cage Shape on Nanoparticle-Based Drug Carriers: Anticancer Drug Release and Efficacy via Receptor Blockade Using Dextran-Coated Iron Oxide Nanocages.

Authors:  Sham Rampersaud; Justin Fang; Zengyan Wei; Kristina Fabijanic; Stefan Silver; Trisha Jaikaran; Yuleisy Ruiz; Murielle Houssou; Zhiwei Yin; Shengping Zheng; Ayako Hashimoto; Ayuko Hoshino; David Lyden; Shahana Mahajan; Hiroshi Matsui
Journal:  Nano Lett       Date:  2016-11-10       Impact factor: 11.189

8.  Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity.

Authors:  Jianren Mao; Backil Sung; Ru-Rong Ji; Grewo Lim
Journal:  J Neurosci       Date:  2002-09-15       Impact factor: 6.167

Review 9.  Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Lobna A Ibrahim; Nancy Diaz-Granados; Carlos A Zarate
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

10.  Dopamine D2 receptor desensitization by dopamine or corticotropin releasing factor in ventral tegmental area neurons is associated with increased glutamate release.

Authors:  Sudarat Nimitvilai; Melissa Herman; Chang You; Devinder S Arora; Maureen A McElvain; Marisa Roberto; Mark S Brodie
Journal:  Neuropharmacology       Date:  2014-03-19       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.